Publication | Open Access

Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

Rheumatoid DisorderRheumatologyEpidemiologyHealth EconomicsBudget Impact AnalysisOsteoarthritisOutcomes ResearchBiosimilar InfliximabPaediatric RheumatologyPharmacoeconomicsInflammatory Rheumatic DiseaseMedicineRheumatoid Arthritis